Aminosilanized flower-structured superparamagnetic iron oxide nanoparticles coupled to 131I-labeled CC49 antibody for combined radionuclide and hyperthermia therapy of cancer
Само за регистроване кориснике
2020
Аутори
Stanković, AljošaMihailović, Jasna
Mirković, Marija D.
Radović, Magdalena
Milanović, Zorana
Ognjanović, Miloš
Janković, Drina
Antić, Bratislav
Mijović, Milica
Vranješ-Đurić, Sanja
Prijović, Željko
Чланак у часопису (Објављена верзија)
,
© 2020 Elsevier B.V.
Метаподаци
Приказ свих података о документуАпстракт
Combined radionuclide therapy with magnetic nanoparticles-mediated hyperthermia has been under research focus as a promising tumor therapy approach. The objective of this study was to investigate the potential of 131I-radiolabeled superparamagnetic iron oxide nanoparticles (SPIONs) prepared as the ~40 nm flower-shaped structures with excellent heating efficiency (specific absorption rate at H0 = 15.9 kA∙m−1 and resonant frequency of 252 kHz was 123.1 W∙g−1) for nano-brachytherapy of tumors. 131I-radiolabeled CC49 antibody attached to SPIONs via reactive groups of 3-aminopropyltriethoxysilane (APTES) provided specificity and long-lasting localized retention after their intratumoral application into LS174T human colon adenocarcinoma xenografts in NOD-SCID mice. The results demonstrate feasibility and effectiveness of magnetic hyperthermia (HT), radionuclide therapy (RT) and their combination (HT + RT) in treating cancer in xenograft models. Combined therapy approach induced a significant... (p < 0.01) tumor growth suppression in comparison to untreated groups presented by the tumor volume inhibitory rate (TVIR): 54.38%, 68.77%, 73.00% for HT, RT and HT + RT, respectively in comparison to untreated group and 48.31%, 64,62% and 69,41%, respectively, for the SPIONs-only injected group. Histopathology analysis proved the necrosis and apoptosis in treated tumors without general toxicity. Obtained data support the idea that nano-brachytherapy combined with hyperthermia is a promising approach for effective cancer treatment.
Кључне речи:
Superparamagnetic nanoparticles / Radionuclide (I-131) therapy / Hyperthermia / CC49 monoclonal antibody / Combined therapy / Nano-brachytherapy / Nano-radiopharmaceuticalsИзвор:
International Journal of Pharmaceutics, 2020, 587, 119628-Финансирање / пројекти:
- Ministry of Education, Science and Technological Development of the Republic of Serbia
DOI: 10.1016/j.ijpharm.2020.119628
ISSN: 0378-5173
PubMed: 32681867
WoS: 000568785100009
Scopus: 2-s2.0-85088953656
Колекције
Институција/група
VinčaTY - JOUR AU - Stanković, Aljoša AU - Mihailović, Jasna AU - Mirković, Marija D. AU - Radović, Magdalena AU - Milanović, Zorana AU - Ognjanović, Miloš AU - Janković, Drina AU - Antić, Bratislav AU - Mijović, Milica AU - Vranješ-Đurić, Sanja AU - Prijović, Željko PY - 2020 UR - https://vinar.vin.bg.ac.rs/handle/123456789/9117 AB - Combined radionuclide therapy with magnetic nanoparticles-mediated hyperthermia has been under research focus as a promising tumor therapy approach. The objective of this study was to investigate the potential of 131I-radiolabeled superparamagnetic iron oxide nanoparticles (SPIONs) prepared as the ~40 nm flower-shaped structures with excellent heating efficiency (specific absorption rate at H0 = 15.9 kA∙m−1 and resonant frequency of 252 kHz was 123.1 W∙g−1) for nano-brachytherapy of tumors. 131I-radiolabeled CC49 antibody attached to SPIONs via reactive groups of 3-aminopropyltriethoxysilane (APTES) provided specificity and long-lasting localized retention after their intratumoral application into LS174T human colon adenocarcinoma xenografts in NOD-SCID mice. The results demonstrate feasibility and effectiveness of magnetic hyperthermia (HT), radionuclide therapy (RT) and their combination (HT + RT) in treating cancer in xenograft models. Combined therapy approach induced a significant (p < 0.01) tumor growth suppression in comparison to untreated groups presented by the tumor volume inhibitory rate (TVIR): 54.38%, 68.77%, 73.00% for HT, RT and HT + RT, respectively in comparison to untreated group and 48.31%, 64,62% and 69,41%, respectively, for the SPIONs-only injected group. Histopathology analysis proved the necrosis and apoptosis in treated tumors without general toxicity. Obtained data support the idea that nano-brachytherapy combined with hyperthermia is a promising approach for effective cancer treatment. T2 - International Journal of Pharmaceutics T1 - Aminosilanized flower-structured superparamagnetic iron oxide nanoparticles coupled to 131I-labeled CC49 antibody for combined radionuclide and hyperthermia therapy of cancer VL - 587 SP - 119628 DO - 10.1016/j.ijpharm.2020.119628 ER -
@article{ author = "Stanković, Aljoša and Mihailović, Jasna and Mirković, Marija D. and Radović, Magdalena and Milanović, Zorana and Ognjanović, Miloš and Janković, Drina and Antić, Bratislav and Mijović, Milica and Vranješ-Đurić, Sanja and Prijović, Željko", year = "2020", abstract = "Combined radionuclide therapy with magnetic nanoparticles-mediated hyperthermia has been under research focus as a promising tumor therapy approach. The objective of this study was to investigate the potential of 131I-radiolabeled superparamagnetic iron oxide nanoparticles (SPIONs) prepared as the ~40 nm flower-shaped structures with excellent heating efficiency (specific absorption rate at H0 = 15.9 kA∙m−1 and resonant frequency of 252 kHz was 123.1 W∙g−1) for nano-brachytherapy of tumors. 131I-radiolabeled CC49 antibody attached to SPIONs via reactive groups of 3-aminopropyltriethoxysilane (APTES) provided specificity and long-lasting localized retention after their intratumoral application into LS174T human colon adenocarcinoma xenografts in NOD-SCID mice. The results demonstrate feasibility and effectiveness of magnetic hyperthermia (HT), radionuclide therapy (RT) and their combination (HT + RT) in treating cancer in xenograft models. Combined therapy approach induced a significant (p < 0.01) tumor growth suppression in comparison to untreated groups presented by the tumor volume inhibitory rate (TVIR): 54.38%, 68.77%, 73.00% for HT, RT and HT + RT, respectively in comparison to untreated group and 48.31%, 64,62% and 69,41%, respectively, for the SPIONs-only injected group. Histopathology analysis proved the necrosis and apoptosis in treated tumors without general toxicity. Obtained data support the idea that nano-brachytherapy combined with hyperthermia is a promising approach for effective cancer treatment.", journal = "International Journal of Pharmaceutics", title = "Aminosilanized flower-structured superparamagnetic iron oxide nanoparticles coupled to 131I-labeled CC49 antibody for combined radionuclide and hyperthermia therapy of cancer", volume = "587", pages = "119628", doi = "10.1016/j.ijpharm.2020.119628" }
Stanković, A., Mihailović, J., Mirković, M. D., Radović, M., Milanović, Z., Ognjanović, M., Janković, D., Antić, B., Mijović, M., Vranješ-Đurić, S.,& Prijović, Ž.. (2020). Aminosilanized flower-structured superparamagnetic iron oxide nanoparticles coupled to 131I-labeled CC49 antibody for combined radionuclide and hyperthermia therapy of cancer. in International Journal of Pharmaceutics, 587, 119628. https://doi.org/10.1016/j.ijpharm.2020.119628
Stanković A, Mihailović J, Mirković MD, Radović M, Milanović Z, Ognjanović M, Janković D, Antić B, Mijović M, Vranješ-Đurić S, Prijović Ž. Aminosilanized flower-structured superparamagnetic iron oxide nanoparticles coupled to 131I-labeled CC49 antibody for combined radionuclide and hyperthermia therapy of cancer. in International Journal of Pharmaceutics. 2020;587:119628. doi:10.1016/j.ijpharm.2020.119628 .
Stanković, Aljoša, Mihailović, Jasna, Mirković, Marija D., Radović, Magdalena, Milanović, Zorana, Ognjanović, Miloš, Janković, Drina, Antić, Bratislav, Mijović, Milica, Vranješ-Đurić, Sanja, Prijović, Željko, "Aminosilanized flower-structured superparamagnetic iron oxide nanoparticles coupled to 131I-labeled CC49 antibody for combined radionuclide and hyperthermia therapy of cancer" in International Journal of Pharmaceutics, 587 (2020):119628, https://doi.org/10.1016/j.ijpharm.2020.119628 . .